Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented new Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists designed for use in the treatment of atopic dermatitis, irritable bowel syndrome, metabolic syndrome, migraine, pain, neuropathic pain, rheumatoid arthritis and urticaria, among others.

Haisco Pharmaceutical Group Co. Ltd. has reported fibroblast growth factor receptor 2 (FGFR2) and FGFR3 inhibitors potentially useful for the treatment of cancer.

Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be useful for the treatment of psychiatric and neurological disorders.

A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.

Chengdu Kendite Biomedical Technology Co. Ltd. has synthesized pyrimidopyrazole compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors. They are reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease, dermatological and inflammatory disorders.

Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented 20-hydroxyeicosatetraenoic acid (20-HETE) production inhibitors. They are reported to be useful for the treatment of cancer, obesity, diabetes, Alzheimer’s and Parkinson’s disease, osteoporosis, cardiovascular and cerebrovascular disorders, among others.

Eracal Therapeutics AG has disclosed compounds acting as appetite suppressants with potential use in the treatment of metabolic syndrome.

Chengdu Cynogen Bio-Pharmaceutical Technology Co. Ltd. has synthesized CDK2/cyclin E1 inhibitors designed for use in the treatment of cancer.

Pfizer Inc. has discovered substituted pyridine compounds acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors and thus described as potentially useful for the treatment of diabetes, chronic kidney disease, nonalcoholic fatty liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.

The Korea Institute of Science and Technology (KIST) and Neocannbio Co. Ltd. have jointly identified compounds acting as nitric oxide (NO) production inhibitors with potential for the treatment of inflammatory bowel disease (IBD).